Drug Trial Radar · NCT06652438
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
448
Planned (sponsor's estimate)
Start
May 5, 2025
Primary completion
Dec 13, 2029
Study completion Aug 27, 2032
Sponsor
- Lead sponsor
- Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- German-Austrian Acute Myeloid Leukemia Study Group; United Kingdom AML Research Network; Beat AML, LLC
- First posted
- Oct 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Treatment of patients with newly diagnosed AML who are not eligible for intensive chemotherapy has remained an area of high unmet medical need. The combination therapy with two medicines, azacitidine and venetoclax, is the usual plan of action. This has brought significant progress in the treatment, but it nevertheless is not curative and the disease does relapse over time. Revumenib blocks a specific molecule called menin in the cell nucleus. Some types of AML are reliant on menin working properly. These are leukemia cells with a change in the DNA, i.e. a mutation in the NPM1 or KMT2A gene. Revumenib can prevent the production of these types of leukemia cells by disrupting the production of this menin. The current study investigates whether adding revumenib to the combination therapy improves the prognosis for AML patients with a mutation in the NPM1 or KMT2A gene. This is a randomized, double-blind, placebo-controlled clinical study where subjects will be treated until disease progression, or development of side effects or death. From the moment of inclusion of the last patient, there will be a 4-year observational follow-up study in order to register survival duration and follow-up visits. Approximately 448 previously untreated patients with a mutation in the NPM1 or KMT2A gene and with newly diagnosed AML, who are not eligible for intensive chemotherapy. Patients must be ≥18 years of age.
Conditions
- Acute Myeloid Leukemia, Adult
Interventions
RevumenibDrug
day 1- 28 per cycle
PlaceboDrug
day 1- 28 per cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS) in adult patients with newly diagnosed NPM1-mutated AML ineligible for intensive chemotherapy.Time frame: 58 months after last patient inclusion
- Rate of CR in adult patients with newly diagnosed NPM1-mutated AML ineligible for intensive chemotherapyTime frame: 58 months after the first randomized NPM1-mutated AML patient
Locations
199 sites in 18 countries. Site status is shown where the registry gives one.
US-Los Angeles CA-UCLA
Los Angeles, California · Not yet recruiting
US-San Francisco CA-UCSF
San Francisco, California · Recruiting
US-Atlanta GA-EMORY
Atlanta, Georgia · Recruiting
US-Kansas City KS-KUMC
Fairway, Kansas · Recruiting
US-Baltimore MD-UMGCCC
Baltimore, Maryland · Recruiting
US-Chapel Hill-UNCNORTHCAROLINA
Chapel Hill, North Carolina · Recruiting
US-Cincinnati OH-CINCY
Cincinnati, Ohio · Recruiting
US-Colombus OH-OSU
Columbus, Ohio · Recruiting
US-Portland OR-OHSU
Portland, Oregon · Not yet recruiting
US-Pittsburgh PA-PITT
Pittsburgh, Pennsylvania · Recruiting
US-Dallas TX-SOUTHWESTERN
Dallas, Texas · Not yet recruiting
US-Wheeling WV-WVU
Wheeling, West Virginia · Recruiting
AU-Adelaide-RAH
Adelaide, Australia · Recruiting
AU-Birtinya-SUNSHINECOASTUH General Information
Birtinya, Australia · Recruiting
AU-Brisbane-RBWH
Brisbane, Australia · Recruiting
AU-Douglas-TOWNSVILLE
Douglas, Australia · Recruiting
AU-Melbourne-ALFRED
Melbourne, Australia · Recruiting
AU-Melbourne-MONASH
Melbourne, Australia · Recruiting
AU-Perth-FSH
Perth, Australia · Withdrawn
AU-Perth-SCGH
Perth, Australia · Recruiting
AU-Sydney-RNSH
Sydney, Australia · Recruiting
AU-Sydney-SVSH
Sydney, Australia · Not yet recruiting
AT-Feldkirch-IKHF
Feldkirch, Austria · Recruiting
AT-Linz-KEPLER
Linz, Austria · Not yet recruiting
AT-Salzburg-SALK
Salzburg, Austria · Not yet recruiting
AT-Vienna-HANUSCH
Vienna, Austria · Recruiting
BE-Antwerpen-ZAS
Antwerp, Belgium · Recruiting
BE-Brugge-AZBRUGGE
Bruges, Belgium · Recruiting
BE-Brussel-BORDET
Brussels, Belgium · Recruiting
BE-Brussel-UZBRUSSEL
Brussels, Belgium · Recruiting
BE-Bruxelles-STLUC
Brussels, Belgium · Recruiting
BE-Gent-UZGENT
Ghent, Belgium · Recruiting
BE-Hasselt-VIRGAJESSE
Hasselt, Belgium · Not yet recruiting
BE-Leuven-UZLEUVEN
Leuven, Belgium · Recruiting
BE-Liege-CHULIEGE
Liège, Belgium · Recruiting
BE-Yvoir-MONTGODINNE
Yvoir, Belgium · Recruiting
DK-Aalborg-AALBORGUH
Aalborg, Denmark · Not yet recruiting
DK-Aarhus N-AUH
Aarhus N, Denmark · Recruiting
DK-Copenhagen-RIGSHOSPITALET
Copenhagen, Denmark · Not yet recruiting
DK-Odense-OUH
Odense, Denmark · Not yet recruiting
Showing 40 of 199 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.